CYCN
Price
$2.42
Change
-$0.09 (-3.59%)
Updated
Sep 3 closing price
Capitalization
7.77M
ENTO
Price
$2.77
Change
+$0.03 (+1.09%)
Updated
Sep 3 closing price
Capitalization
4.4M
Interact to see
Advertisement

CYCN vs ENTO

Header iconCYCN vs ENTO Comparison
Open Charts CYCN vs ENTOBanner chart's image
Cyclerion Therapeutics
Price$2.42
Change-$0.09 (-3.59%)
Volume$17.03K
Capitalization7.77M
Entero Therapeutics
Price$2.77
Change+$0.03 (+1.09%)
Volume$114.06K
Capitalization4.4M
CYCN vs ENTO Comparison Chart in %
Loading...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCN vs. ENTO commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCN is a Hold and ENTO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (CYCN: $2.42 vs. ENTO: $2.77)
Brand notoriety: CYCN and ENTO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCN: 40% vs. ENTO: 5%
Market capitalization -- CYCN: $7.77M vs. ENTO: $4.4M
CYCN [@Biotechnology] is valued at $7.77M. ENTO’s [@Biotechnology] market capitalization is $4.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCN’s FA Score shows that 1 FA rating(s) are green whileENTO’s FA Score has 1 green FA rating(s).

  • CYCN’s FA Score: 1 green, 4 red.
  • ENTO’s FA Score: 1 green, 4 red.
According to our system of comparison, ENTO is a better buy in the long-term than CYCN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCN’s TA Score shows that 5 TA indicator(s) are bullish while ENTO’s TA Score has 5 bullish TA indicator(s).

  • CYCN’s TA Score: 5 bullish, 4 bearish.
  • ENTO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both CYCN and ENTO are a good buy in the short-term.

Price Growth

CYCN (@Biotechnology) experienced а -5.64% price change this week, while ENTO (@Biotechnology) price change was +45.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYCN($7.77M) has a higher market cap than ENTO($4.4M). ENTO YTD gains are higher at: 48.446 vs. CYCN (-24.689). ENTO has more cash in the bank: 11.4M vs. CYCN (3.01M). CYCN has less debt than ENTO: CYCN (0) vs ENTO (836K).
CYCNENTOCYCN / ENTO
Capitalization7.77M4.4M177%
EBITDA-3.76MN/A-
Gain YTD-24.68948.446-51%
P/E RatioN/A0.03-
Revenue2.17MN/A-
Total Cash3.01M11.4M26%
Total Debt0836K-
FUNDAMENTALS RATINGS
CYCN vs ENTO: Fundamental Ratings
CYCN
ENTO
OUTLOOK RATING
1..100
2137
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
7935
P/E GROWTH RATING
1..100
10089
SEASONALITY SCORE
1..100
250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENTO's Valuation (8) in the null industry is in the same range as CYCN (14). This means that ENTO’s stock grew similarly to CYCN’s over the last 12 months.

ENTO's Profit vs Risk Rating (100) in the null industry is in the same range as CYCN (100). This means that ENTO’s stock grew similarly to CYCN’s over the last 12 months.

CYCN's SMR Rating (96) in the null industry is in the same range as ENTO (100). This means that CYCN’s stock grew similarly to ENTO’s over the last 12 months.

ENTO's Price Growth Rating (35) in the null industry is somewhat better than the same rating for CYCN (79). This means that ENTO’s stock grew somewhat faster than CYCN’s over the last 12 months.

ENTO's P/E Growth Rating (89) in the null industry is in the same range as CYCN (100). This means that ENTO’s stock grew similarly to CYCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCNENTO
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 25 days ago
89%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TCRX1.870.12
+6.86%
TScan Therapeutics
ATYR5.710.06
+1.06%
aTyr Pharma Inc
BSY53.41-0.89
-1.64%
Bentley Systems
MYNZ1.66-0.03
-1.78%
Mainz Biomed N.V.
WRD8.99-0.17
-1.86%
WeRide Inc

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with JANX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then JANX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
-3.39%
JANX - CYCN
41%
Loosely correlated
+0.79%
HRTX - CYCN
40%
Loosely correlated
+0.76%
GDTC - CYCN
31%
Poorly correlated
-2.74%
ENTO - CYCN
25%
Poorly correlated
+1.09%
CGEN - CYCN
23%
Poorly correlated
-0.70%
More

ENTO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTO has been loosely correlated with IVVD. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTO jumps, then IVVD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTO
1D Price
Change %
ENTO100%
+1.09%
IVVD - ENTO
65%
Loosely correlated
+0.97%
SRRK - ENTO
38%
Loosely correlated
+3.80%
RLMD - ENTO
36%
Loosely correlated
+3.52%
NEVPF - ENTO
31%
Poorly correlated
N/A
CABA - ENTO
29%
Poorly correlated
+8.28%
More